NCT05926726 is a NA clinical trial of CAR-GPC3 T cells in Hepatocellular Carcinoma, sponsored by RenJi Hospital.

Who is sponsoring NCT05926726?

NCT05926726 is sponsored by RenJi Hospital.

What drugs are being tested in NCT05926726?

Interventions in NCT05926726: CAR-GPC3 T cells.

What condition does NCT05926726 study?

NCT05926726 studies Hepatocellular Carcinoma.

Is NCT05926726 still recruiting?

NCT05926726 is currently recruiting now. Last updated 3 July 2023.

Last reviewed 2023-07-03 · How we verify

NCT05926726

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

Recruiting now NA Last updated 3 July 2023

What this trial tests

NA trial testing CAR-GPC3 T cells in Hepatocellular Carcinoma in 12 participants. Currently enrolling.

Timeline

1 January 2023

Primary endpoint
31 December 2025

31 December 2026

Quick facts

Lead sponsor	RenJi Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 January 2023
Primary completion	31 December 2025
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

CAR-GPC3 T cells — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

RenJi Hospital

Who can join

Adults 18 to 75, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infused autologous armored GPC3-directed CAR-T in patients with advanced hepatocellular carcinoma refractory to prior systematic treatments.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CAR-T Cell Therapy: From the Shop to Cancer Therapy.
Uscanga-Palomeque AC, Chávez-Escamilla AK, Alvizo-Báez CA, Saavedra-Alonso S, et al · · 2023 · cited 60× · PMID 37958672 · DOI 10.3390/ijms242115688
Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma.
Sadagopan N, He AR. · · 2024 · cited 26× · PMID 38279258 · DOI 10.3390/ijms25021259
Targeting Glypican-3 for Liver Cancer Therapy: Clinical Applications and Detection Methods.
Zhang J, Li R, Tan X, Wang C. · · 2025 · cited 9× · PMID 40862283 · DOI 10.14218/jcth.2025.00099
Molecular and immune landscape of hepatocellular carcinoma for therapeutic development.
Suzuki H, Mishra S, Paul S, Hoshida Y. · · 2025 · cited 8× · PMID 39639434 · DOI 10.17998/jlc.2024.12.02
Targeting glypican-3 as a new frontier in liver cancer therapy.
Wu CS, Lee TY, Chao HW. · · 2025 · cited 5× · PMID 41024885 · DOI 10.4254/wjh.v17.i9.107671
Insights in Molecular Therapies for Hepatocellular Carcinoma.
Heumann P, Albert A, Gülow K, Tümen D, et al · · 2024 · cited 5× · PMID 38791911 · DOI 10.3390/cancers16101831
Advances and challenges of chimeric antigen receptor T cell therapy in digestive system malignancies.
Wang C, Zhang J, Chen ZK, Wang YG, et al · · 2026 · PMID 41810338 · DOI 10.5306/wjco.v17.i2.114107
Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy.
Hassanel DNBP, Sharma A. · · 2026 · PMID 41780553 · DOI 10.3350/cmh.2025.1410

Verify or expand the search:

Other trials of CAR-GPC3 T cells

Trials testing the same drug.

NCT03146234 — CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma · NA · completed

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other RenJi Hospital trials

Trials by the same sponsor.

NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05926726 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
Last refreshed: 3 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05926726.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing